Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tovey, E.
Right arrow Articles by Livingstone, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tovey, E.
Right arrow Articles by Livingstone, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice

Elizabeth Tovey

West London Mental Health NHS Trust, John Conolly Wing, Middlesex, UK

Hagen Rampes

Barnet, Enfield and Haringey Mental Health NHS Trust, North West Community Mental Health Team, Edgware, Middlesex, UK, Hagen.Rampes{at}beh-mht.nhs.uk

Callum Livingstone

Clinical Biochemistry Department, Royal Surrey County Hospital, Guildford, Surrey, UK

The atypical antipsychotic clozapine has been reported to be associated with metabolic adverse effects, including type-2 diabetes mellitus. We present two cases of diabetes mellitus associated with clozapine treatment. One case resolved entirely upon withdrawal of the drug, whereas the other did not. We discuss the molecular basis of the diabetogenic action of clozapine and recommendations for monitoring.

Key Words: adverse effect • antipsychotic • clozapine • diabetes mellitus • schizoaffective disorder • schizophrenia

Journal of Psychopharmacology, Vol. 19, No. 2, 207-210 (2005)
DOI: 10.1177/0269881105049043
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
M Zink, A Kuwilsky, B Krumm, and H Dressing
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial
J Psychopharmacol, May 1, 2009; 23(3): 305 - 314.
[Abstract] [PDF]


Advertisement